Open an account

EyePoint

EYPT · NASDAQ

$0.4052−$0.0348 (−7.91%)TodayMarket closed ·
Prev close $0.44

About EYPT

EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 214 full-time employees. The company went IPO on 2005-01-27. The firm is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Employees
214
Headquarters
Watertown, Massachusetts
Listed
Jan 27, 2005
Sector
Health Care
Industry
Pharmaceuticals
Website
eyepoint.bio

EYPT key statistics

Market cap
34.93M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
11.85M
Volume
51.03M
Open price
$0.4174
High today
$0.4751
Low today
$0.405
52 Week high
$19.11
52 Week low
$0.4025

EyePoint (EYPT) at a glance

As of Oct 20, 2026, EyePoint (EYPT) shares are priced at $0.4052, giving the company a market cap of 34.93M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.405 and $0.4751. The current price is 0.0% above the day's low and 14.7% below its high.

Volume so far is 51.03M shares, above the average of 11.85M shares a day.

Over the past year EyePoint has ranged from $0.4025 to $19.11, and now sits 0% of the way up that range.

EyePoint met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$1.09 per share against an estimate of -$0.9705.

The average analyst price target is $29.17, 7099.4% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

42%of 12 analyst ratings say Buy
  • Buy41.7%
  • Hold50.0%
  • Sell8.3%
Price target · 12 analystsAvg $29.17
Low
$4.04
Now
$0.4052
High
$71.40

EYPT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 3.8% on average.

  1. Q3 FY24: reported -$0.54 per share against an estimate of -$0.5678
  2. Q4 FY24: reported -$0.64 per share against an estimate of -$0.5113
  3. Q1 FY25: reported -$0.65 per share against an estimate of -$0.6686
  4. Q2 FY25: reported -$0.85 per share against an estimate of -$0.813
  5. Q3 FY25: reported -$0.85 per share against an estimate of -$0.8005
  6. Q4 FY25: reported -$0.81 per share against an estimate of -$0.7627
  7. Q1 FY26: reported -$0.99 per share against an estimate of -$0.824
  8. Q2 FY26: reported -$1.09 per share against an estimate of -$0.9705

EYPT news

  • Press releasePRNewswire

    EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals

  • Shivdeep Dhaliwal

    Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today

  • Press releasePRNewswire

    EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)

  • Avi Kapoor

    Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October

  • Vandana Singh

    EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Avi Kapoor

    Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Similar companies

Companies in the same industry as EyePoint

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.